Increasing Demand in Hospitals and Diagnostic Laboratories to Augment the Growth of the Cell Counting Devices Market

Hospitals and diagnostic laboratories are expected to grow significantly during the forecast period. This can be attributed to an increase in capital expenditure for developing cell culture-based vaccines and the pharmaceutical industry's rapid expansion. Furthermore, rising government policies promoting stem cell development and research, as well as the widespread use of cell counting in medical operations, are expected to boost overall demand for cell counting in hospitals and diagnostic laboratories in the coming years. These factors are expected to fuel industry growth during the forecast period.

According to Data Bridge Market Research the Cell Counting Devices Market is expected to grow with a CAGR of 10.60% in the forecast period of 2021 to 2028.

“Strategies Adopted by Key Players Are Expected to Boost the Global Cell Counting Devices Market Growth”

Key players' strategies such as partnerships, collaborations, and mergers and acquisitions are expected to drive growth in the global cell counting devices market during the forecast period. For instance, Corning Inc., a manufacturer of material science products entered into an agreement with CytoSMART Technologies B.V. in February 2018 to develop a device for simplifying mammalian cell counting in laboratories. CytoSMART created a new technology that was used in Corning Inc.'s cell counting device. The new technology allows for a faster cell counting process.

What restraints the growth of Cell Counting Devices Market?

“Risks associated with cell analysis are expected to hamper the market's growth”

Hemocytometer-based cell counts have a range of drawbacks. These flaws include, but are not restricted to a lack of statistical robustness at low sample concentration, inaccurate counts brought on by improper device use and subjectivity of user counts. The high cost of cell analysis may hamper the market expansion, a shortage of highly educated workers and an inadequate infrastructure for conducting research, particularly in developing and undeveloped countries.

Segmentation: Cell Counting Devices Market

The cell counting devices market is segmented on the basis of product type, application and end user. 

  • Based on the product type, the cell counting devices market is segmented into consumables and accessories, instruments.
  • Based on the application, the cell counting devices market is segmented into research applications, clinical and diagnostic applications, industrial applications.
  • Based on the end-user, the cell counting devices market is segmented into hospitals and diagnostic centers, research institutions, pharmaceutical and biotechnology companies, contract research organizations (CROs), other end users.

Regional Insights: North America is expected to dominate the Cell Counting Devices Market

North America is expected to dominate the market due to improved healthcare infrastructure, rising government initiative for research and development activities across various countries in this region. Furthermore, the presence of major key players such as Thermo Fisher Scientific, GE Healthcare and others is expected to boost market growth in this region.

In addition, the Asia-Pacific region is likely to register highest growth rate during the forecast period of 2022 to 2029 due to the rising prevalence of chronic disorders like blood and cardiovascular diseases. The region's market for cell counting devices will also rise as a result of improved healthcare infrastructure and an expansion of government-sponsored research and development initiatives in the field of stem cells. Furthermore, the region's market growth can be attributed to an increase in the number of proteomics and genomics researchers, as well as increased investments by pharmaceutical and biotechnology companies in the region. Furthermore, the presence of a diverse range of medical research and biopharmaceutical businesses is expected to drive market growth in the coming years.

To know more about the study visit,

Recent Developments in Cell Counting Devices Market

  • In 2022, Mindray introduced the new BC-700 Series, a revolutionary haematology analyzer series that includes complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests.
  • In 2022, Abacus dx entered into a new partnership with Luminex for their Guava range of flow cytometry instruments and reagents. Abacus dx distributed the Luminex's Guava line of flow cytometry instruments and reagents as part of the collaboration.

The Prominent Key Players Operating in the Cell Counting Devices Market Include:

  • Agilent Technologies, Inc. (U.S.)
  • Abbott (U.S.)
  • BD (U.S.)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • BioTek Instruments, Inc. (U.S.)
  • Danaher (U.S.)
  • F. Hoffmann-La Roche AG (Switzerland)
  • GE Healthcare (U.S.)
  • HORIBA Ltd. (Japan)
  • Merck & Co., Inc. (U.S.)
  • PerkinElmer, Inc. (U.S.)
  • Siemens Healthcare GmbH (Germany)
  • Sysmex Corporation (Japan)
  • Thermo Fisher Scientific (U.S.)
  • Corning Incorporated (U.S.)

Above are the key players covered in the report, to know about more and exhaustive list of cell counting devices   market companies contact,

Research Methodology: Global Cell Counting Devices Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.